PUBLISHER: The Insight Partners | PRODUCT CODE: 2021161
PUBLISHER: The Insight Partners | PRODUCT CODE: 2021161
The Compression Therapy market is anticipated to grow from US$ 2.39 Billion in 2025 to US$ 3.44 Billion by 2034; the market is expected to register a CAGR of 4.2% from 2026 to 2034. Compression Therapy Market growth is attributed to the rising prevalence of venous and lymphatic disorders driving therapy adoption, increasing technological advancements and new product innovations, and aging populations and increasing chronic disease.
Compression therapy is a medical treatment that uses controlled pressure, typically through garments, bandages, or devices, to improve blood circulation and lymphatic flow in affected areas. It is widely used to manage conditions such as varicose veins, lymphedema, deep vein thrombosis, and chronic venous insufficiency. By applying graduated pressure, it helps reduce swelling, prevent fluid buildup, and enhance venous return. Compression therapy is commonly used in hospitals, clinics, and home care settings, and plays a key role in post-surgical recovery, wound healing, and long-term management of chronic vascular conditions.
The compression therapy market in North America is segmented into the US, Canada, and Mexico. The US compression therapy market is expanding due to high and sustained prevalence of vascular and lymphatic conditions, evolving policy coverage, and continued clinical innovation. According to the CDC, venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism, affects up to 900,000 Americans annually, with many cases preventable through mechanical measures like compression therapy, highlighting a large at-risk population requiring clinical management. Additionally, chronic venous insufficiency (CVI), a major indication for compression products, is estimated to affect between 10% and 35% of US adults, with complications such as venous ulcers more common in older adults. Lymphedema also remains prevalent, with at least five million Americans living with the condition, and roughly half of them covered under Medicare Part B starting in 2024 for medically prescribed compression garments and supplies, according to the Centers for Medicare & Medicaid Services (CMS).
Policy changes such as the implementation of the Lymphedema Treatment Act beginning January 1, 2024, mandating Medicare coverage for prescribed compression treatment items, have expanded reimbursement and reduced cost barriers for beneficiaries, encouraging higher clinician prescriptions and patient uptake. Clinically, updated HCPCS coding expansions in 2025 support detailed billing for diverse compression garments, improving access and provider participation. Meanwhile, device advancements continue, with healthcare manufacturers introducing next-generation pneumatic compression systems and improved garment designs to address both clinical and home care needs. These combined epidemiological, policy, and product innovation factors underpin the growing demand for compression therapy across US healthcare settings in 2023-2025.
Government Driven Coverage & Reimbursement Expansion to Provide Market Opportunities in Future
An important opportunity for compression therapy stems from public health policy changes that improve insurance coverage for medically prescribed compression products, reducing financial barriers and driving wider clinical adoption. For example, the US Lymphedema Treatment Act (H.R. 3630) was enacted to amend Medicare rules so that medically necessary gradient compression garments and related treatment items prescribed for lymphedema are covered under the Medicare program starting in 2024. According to the Congressional text, this coverage applies to both standard and custom-fitted compression therapy items when prescribed by a qualified clinician, which is expected to improve access for millions of beneficiaries who previously faced out-of-pocket costs for these essential supplies.
This legislative shift not only reduces out-of-pocket burden for patients with chronic lymphatic conditions but also sets a precedent for Medicaid and private insurers to follow, potentially expanding coverage across wider populations. As reimbursement becomes more predictable, healthcare providers and manufacturers can invest in product innovations and clinical education initiatives with greater confidence, driving higher adoption of compression therapy solutions in standard chronic disease management pathways.
World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), American Chemical Society Publications, The U.S. Centers for Medicare & Medicaid Services (CMS), The Longitudinal Ageing Study of India (LASI), Centers for Medicare & Medicaid Services (CMS), National Center for Biotechnology Information (NCBI). National Institutes of Health (NIH). the US Food and Drug Administration, Mexican government health surveys (ENSANUT), Institut national de la statistique et des etudes economiques (INSEE), Istituto Superiore di Sanita (ISS) PASSI surveillance, Eurostat, the Italian Ministry of Health and ISS care pathway guidelines, United Nations Economic and Social Commission for Asia and the Pacific (UN ESCAP), China's National Health Commission statistics, the Ministry of Health, Labour and Welfare (MHLW), the Indian Council of Medical Research's (ICMR), Korea National Health and Nutrition Examination Survey (KNHANES), Ministry of Health National Population Health Survey, Malaysian National Health and Morbidity Survey are among the primary and secondary sources referred to while preparing the compression therapy market report.